Table 2.

Treatment-related AEs (≥ 3 participants)*

Event type	25 mg/240 mg† N=55
Nausea	14 (25.5) [19]
Fatigue	12 (21.8) [17]
Diarrhea	10 (18.2) [16]
Decreased appetite	8 (14.5) [9]
Pyrexia	7 (12.7) [8]
Pruritus	6 (10.9) [6]
Alanine aminotransferase increased	5 (9.1) [6]
Aspartate aminotransferase increased	4 (7.3) [6]
Chills	3 (5.5) [3]
Pneumonitis	3 (5.5) [3]

*50 mg pixatimod/240 mg nivolumab data not presented as only three participants were recruited.

†For any given AE, the results are presented as the number of participants with the event: n, the proportion of participants with the event: (%), and the number of events: [e].

AEs, adverse events.